
Rose Gerber
@rosegerbercoa
Director of Patient Advocacy & Education, Community Oncology Alliance. Cancer Survivor. Clinical Trial Participant
ID: 158135883
http://www.coaAdvocacy.org 21-06-2010 21:57:48
1,1K Tweet
494 Followers
1,1K Following

Hospitals participating in the 340B program are financially incentivized to prescribe original biologics to prevent and treat diseases in lieu of cheaper generic-like alternatives called biosimilars, according to a new study - from Weill Cornell Medicine news.weill.cornell.edu/news/2023/06/f…

Only 67 Practices In New Oncology Model After Practices Raised Concerns - from InsideHealthPolicy ow.ly/lFLQ50P2CMN



Thank you Rep. Colin Allred Congresswoman Jasmine Crockett Eleanor #DCStatehood Holmes Norton Raul M. Grijalva and ARCHIVE: Congresswoman Ann McLane Kuster for cosponsoring the Comprehensive Cancer Survivorship Act (H.R. 4363/S. 2213) and supporting cancer survivors and their families!





At last month's House Oversight Committee hearing on PBMs, arguably no congressman stood out more than Rep. Jake Auchincloss 🟧, who clearly has an exceptional grasp on how drug pricing actually works and how PBMs exacerbate affordability problems for plan sponsors and patients. A+



I know it's frustrating but Congress has made strides in stopping #PBM abuses w/ Energy and Commerce Committee & Senate Finance Committee committees passing legislation aimed to stopping #PBMs. The ship moves slow but is moving, pushed on by states doing the same. PBMs are brazen but also running scared.





"It's not (insert political party's) cancer. You have to reach across the aisle to get good policy passed." Rose Gerber @MaryKCaffrey Neil Foley of NYCancerSpecialists and Emily Touloukian, DO, of Coastal Cancer Center talk advocacy at #COA2024


DIR fees are gone and all is well. Right? PBMs are sneakier than that, unfortunately. Kathy Oubre, Jon Levitt of @frierlevitt, Jeff Mortier, and Jeff Vacirca, MD discuss the workarounds that PBMs have created to keep that DIR fee money.
